

TO/92/40
U.S. PTO
83126

04.27-01

PATENT A

UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))


USPTO
83126
04/26/01

Commissioner of Patents
Box Patent Application
Washington, D.C. 20231
Sir:

Transmitted herewith for filing is the patent application
under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: CA2413-US NP
INVENTORS: ASTLES, Peter et al.
TITLE: CHEMICAL COMPOUNDS

I hereby certify that this correspondence is being
deposited with the United States Postal Service
Express Mail in an envelope addressed to:
Commissioner for Patents, Washington, D.C. 20231
on

26 April 2001

Signature

EL608058688US
Express Mail No.

APPLICATION ELEMENTS

1. *Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. Specification Total Pages 164
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (*if filed*)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. Drawing(s) (35 U.S.C. 113) Total Sheets
4. Oath or Declaration Total Pages 3
 - a. Newly executed (original or copy) (UNSIGNED)
 - b. Copy from a prior application (37 CFR § 1.63(d))
(for continuation/divisional with Box 16 completed)
 - i. DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).
5. Microfiche Computer Program (*Appendix*)
6. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
 - a. Computer Readable Copy
 - b. Paper Copy (identical to computer copy)
 - c. Statement verifying identity of above copies

If a **CONTINUING Application**, check appropriate box, and supply the requisite information:

Continuation Divisional Continuation-in-part

of prior application no: _____, filed _____

Examiner _____, Group/Art Unit _____.

(The cross reference has been/will be inserted on page one of the specification).

This application claims the benefit of U.S. Provisional Application No. _____, filed _____. (The cross reference has been/will be inserted on page one of the specification).

Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.)

The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

ACCOMPANYING APPLICATION PARTS


7. Assignment Papers (*cover sheet & document(s)*)
8. 37 CFR §3.73(b) Statement Power of Attorney
(*when there is an assignee*)
9. English Translation Document (*if applicable*)
10. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations
11. Preliminary Amendment
12. Return Receipt Postcard (MPEP 503)
(*Should be specifically itemized*)
13. *Small Entity Statement(s) Statement filed in prior application,
(*PTO/SB/09-12*) Status still proper and desired
14. Certified Copy of Priority Document(s)
(*if foreign priority is claimed*)
15. Other: 1-CDR for Table 4 (in duplicate) 37 CFR § 1.52
2-Transmittal Letter for Compact Discs

CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label

005487

(Insert Customer No. or Attach bar code label here)


William C. Coppola, Reg. No. 41,686
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Mail Code: EMC-G1
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4854
Telefax (908) 231-2626

Aventis Docket No. CA2413-US NP

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT

(\$ 1,726.00)

Complete if Known

Application Number	Not yet assigned
Filing Date	Herewith
First Named Inventor	ASTLES, Peter et al.
Examiner Name	Not yet assigned
Group / Art Unit	Not yet assigned
Attorney Docket No.	CA2413-US NP

METHOD OF PAYMENT

1. The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number **18-1982**Deposit Account Name **Aventis Pharmaceuticals Products Inc.**

- Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17
 Applicant claims small entity status. See 37 CFR 1.27

2. Payment Enclosed:

- Check Credit Card Money Order Other

FEE CALCULATION**1. BASIC FILING FEE**

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
101	710	201	355	Utility filing fee	710
106	320	206	160	Design filing Fee	
107	490	207	245	Plant filing fee	
108	710	208	355	Reissue filing fee	
114	150	214	75	Provisional filing fee	

SUBTOTAL (1) (\$710)**2. EXTRA CLAIM FEES**

	Extra Claims	Fee from below	Fee Paid
Total Claims	72	-20**= 52	x 18 = 936
Independent Claims	4	- 3**= 1	x 80 = 80
Multiple Dependent			270 = 0

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description
103	18	203	9	Claims in excess of 20
102	80	202	40	Independent claims in excess of 3
104	270	204	135	Multiple dependent claim, if not paid
109	80	209	40	**Reissue independent claims over original patent
110	18	210	9	**Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$1016.00)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)**3. ADDITIONAL FEES**

Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Fee Description	Fee Paid	
				Fee	Paid
105	130	205	Surcharge - late filing fee or oath		
127	50	227	Surcharge - late provisional filing fee or cover sheet		
139	130	139	Non-English Specification		
147	2,520	147	For filing a request for reexamination		
112	920*	112	Requesting publication of SIR prior to Examiner action		
113	1,840*	113	Requesting publication of SIR after Examiner action		
115	110	215	Extension for reply within first month		
116	390	216	Extension for reply within second month		
117	890	217	Extension for reply within third month		
118	1,390	218	Extension for reply within fourth month		
128	1,890	228	Extension for reply within fifth month		
119	310	219	Notice of Appeal		
120	310	220	Filing a brief in support of an appeal		
121	270	221	Request for oral hearing		
138	1,510	138	1,510 Petition to institute a public use proceeding		
140	110	240	55 Petition to revive - unavoidable		
141	1,240	241	620 Petition to revive - unintentional		
142	1,240	242	620 Utility issue fee (or reissue)		
143	440	243	220 Design issue fee		
144	600	244	300 Plant issue fee		
122	130	122	130 Petitions to the Commissioner		
123	50	123	50 Petitions related to provisional applications		
126	180	126	180 Submission of Information Disclosure Stmt		
581	40	581	40 Recording each patent assignment per property (times number of properties)		
146	710	246	355 Filing a submission after final rejection (37 CFR § 1.129(a))		
149	710	249	355 For each additional invention to be examined (37 CFR § 1.129(b))		
179	710	279	355 Request for Continued Examination (RCE)		
169	900	169	900 Request for expedited examination of a design application		
Other fee (specify)					

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)**SUBMITTED BY**Name (Print/Type) **William C. Coppola**Registration No.
(Attorney/Agent)**41,686**Telephone **(908) 231-4854**Signature Date **5/26/01**

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PATENT
CA2413-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): ASTLES, ET AL. EXAMINER : UNASSIGNED
SERIAL NO. : UNASSIGNED ART UNIT : UNASSIGNED
FILED : APRIL 26, 2001
FOR : CHEMICAL COMPOUNDS

CERTIFICATE OF MAILING UNDER 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as EXPRESS MAIL with label No. EL608058688US in an envelope addressed to the ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231 on April 26, 2001.

William C. Coppola, Reg. No. 41,686
(Name of Registered Representative)


(Signature and Date)

TRANSMITTAL LETTER ACCOMPANYING SUBMISSION OF COMPACT DISCS
UNDER 37 CFR 1.52

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

Dear Sir:

Pursuant to 37 CFR 1.52, Applicants submit the instant transmittal letter to accompany two (2) compact discs being filed with the above-identified Application on April 26, 2001. The two enclosed compact discs are identical. In the event that, for some reason, the discs are not identical, the United States Patent and Trademark Office will use the compact disc labeled "Copy 1" for further processing. The following information pertains to both discs:

1. Format for discs: IBM-PC;
2. Operating System for discs: MS-Windows;
3. File on discs: Table 4 of the above-identified Application, filed with the United States Patent and Trademark Office via Express mail on April 26, 2001;
4. Size of File on discs: 237 KB; and
5. Creation Date of discs: April 23, 2001.

CONCLUSION

Early and favorable action on the claims is earnestly solicited.

Respectfully submitted,



William C. Coppola
Attorney for Applicant(s)
Registration No. 41,686

AVENTIS PHARMACEUTICALS PRODUCTS INC.
Route 202-206; Mail Stop: EMC-G1
P.O. Box 6800
Bridgewater, NJ 08807